Archives of Pharmacal Research

, Volume 34, Issue 11, pp 1843–1863 | Cite as

Herb-drug interactions: Focus on metabolic enzymes and transporters



As the uses of herbal medicines from traditional natural products are increased, the need for pharmacokinetic studies and relevant data are also increased for safe pharmacotherapy. The market entry for the traditional herbal medicine is easier compared with that for synthetic drugs because of a lower regulatory barrier. Thus, the exact mechanisms for the absorption, distribution, metabolism and excretion of active components in herbal medicines and the potential herb-drug interactions are not always fully understood. Recently, there has been an increasing interest in pharmacokinetic studies of herbal remedies and relevant data of commonly used herbal remedies are accumulating in this field. In this review, the effects of nine botanicals (ginkgo, green tea, grapes, licorice, saw palmetto, garlic milk thistle, ginseng and St. John’s wort) on metabolic enzymes and transporters affecting absorption and disposition of herbal products are summarized. The source of samples (extracts and individual components), the species (human and animal) and in vivo and in vitro systems were separately reviewed for a better understanding of herb-drug interactions.

Key words

Herb-drug interaction P450 Transporter Pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abernethy, D. R., Kaminsky, L. S., and Dickinson, T. H., Selective inhibition of warfarin metabolism by diltiazem in humans. J. Pharmacol. Exp. Ther., 257, 411–415 (1991).PubMedGoogle Scholar
  2. Alfaras, I., Pérez, M., Juan, M. E., Merino, G., Prieto, J. G., Planas, J. M., and Alvarez, A. I., Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J. Agric. Food Chem., 58, 4523–4528 (2010).PubMedCrossRefGoogle Scholar
  3. Amagase, H., Petesch, B. L., Matsuura, H., Kasuga, S., and Itakura, Y., Intake of garlic and its bioactive components. J. Nutr., 131, 955S–962S (2001).PubMedGoogle Scholar
  4. An, G., Gallegos, J., and Morris, M. E., The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab. Dispos., 39, 426–432 (2011).PubMedCrossRefGoogle Scholar
  5. Anke, J. and Ramzan, I., Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J. Ethnopharmacol., 93, 153–160 (2004).PubMedCrossRefGoogle Scholar
  6. Beckmann-Knopp, S., Rietbrock, S., Weyhenmeyer, R., Böcker, R. H., Beckurts, K. T., Lang, W., Hunz, M., and Fuhr, U., Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol. Toxicol., 86, 250–256 (2000).PubMedCrossRefGoogle Scholar
  7. Bent, S., Kane, C., Shinohara, K., Neuhaus, J., Hudes, E. S., Goldberg, H., and Avins, A. L., Saw palmetto for benign prostatic hyperplasia. N. Engl. J. Med., 354, 557–566 (2006).PubMedCrossRefGoogle Scholar
  8. Bertilsson, L., Carrillo, J. A., Dahl, M. L., Llerena, A., Alm, C., Bondesson, U., Lindström, L., Rodriguez, de la R. I., Ramos, S., and Benitez, J., Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol., 38, 471–473 (1994).PubMedGoogle Scholar
  9. Bobrowska-Hägerstrand, M., Lillås, M., Mrówczyñska, L., Wróbel, A., Shirataki, Y., Motohashi, N., and Hägerstrand, H., Resveratrol oligomers are potent MRP1 transport inhibitors. Anticancer Res., 26, 2081–2084 (2006).PubMedGoogle Scholar
  10. Brill, S. S., Furimsky, A. M., Ho, M. N., Furniss, M. J., Li, Y., Green, A. G., Bradford, W. W., Green, C. E., Kapetanovic, I. M., and Iyer, L. V., Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms. J. Pharm. Pharmacol., 58, 469–479 (2006).PubMedCrossRefGoogle Scholar
  11. Budzinski, J. W., Foster, B.C., Vandenhoek, S., and Arnason, J. T., An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine, 7, 273–282 (2000).PubMedCrossRefGoogle Scholar
  12. Burstein, A. H., Horton, R. L., Dunn, T., Alfaro, R. M., Piscitelli, S. C., and Theodore, W., Lack of effect of St John’s Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther., 68, 605–612 (2000).PubMedCrossRefGoogle Scholar
  13. Butterweck, V. and Schmidt, M., St. John’s wort: role of active compounds for its mechanism of action and efficacy. Wien. Med. Wochenschr., 157, 356–361 (2007).PubMedCrossRefGoogle Scholar
  14. Cai, Z., Qian, T., Wong, R., and Jiand, Z., Liquid chromatography-electrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3. Anal. Chim. Acta, 492, 283–293 (2003).CrossRefGoogle Scholar
  15. Cech, N. B., Tutor, K., Doty, B. A., Spelman, K., Sasagawa, M., Raner, G. M., and Wenner, C. A., Liver enzyme-mediated oxidation of Echinacea purpurea alkylamides: production of novel metabolites and changes in immunomodulatory activity. Planta Med., 72, 1372–1377 (2006).PubMedCrossRefGoogle Scholar
  16. Chan, W. K. and Delucchi, A. B., Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci., 67, 3103–3112 (2000).PubMedCrossRefGoogle Scholar
  17. Chang, T. K., Chen, J., and Benetton, S. A., In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab. Dispos., 30, 378–384 (2002).PubMedCrossRefGoogle Scholar
  18. Chen, Y., Xie, S., Chen, S., and Zeng, S., Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9. Biochem. Pharmacol., 76, 416–425 (2008).PubMedCrossRefGoogle Scholar
  19. Chin, Y. W., Jung, H. A., Liu, Y., Su, B. N., Castoro, J. A., Keller, W. J., Pereira, M. A., and Kinghorn, A. D., Antioxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra). J. Agric. Food Chem., 55, 4691–4697 (2007).PubMedCrossRefGoogle Scholar
  20. Choi, J. S., Choi, B. C., and Kang, K. W., Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Pharmazie, 64, 49–52 (2009).PubMedGoogle Scholar
  21. Chow, H. H., Garland, L. L., Hsu, C. H., Vining, D. R., Chew, W. M., Miller, J. A., Perloff, M., Crowell, J. A., and Alberts, D. S., Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. (Phila), 3, 1168–1175 (2010).CrossRefGoogle Scholar
  22. Christensen, L. P., Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv. Food Nutr. Res., 55, 1–99 (2009).PubMedCrossRefGoogle Scholar
  23. Chrungoo, V. J., Reen, R. K., Singh, K., and Singh, J., Effects of silymarin on UDP-glucuronic acid and glucuronidation activity in the rat isolated hepatocytes and liver in relation to D-galactosamine toxicity. Indian J. Exp. Biol., 35, 256–263 (1997).PubMedGoogle Scholar
  24. Clayton, N. P., Yoshizawa, K., Kissling, G. E., Burka, L. T., Chan, P. C., and Nyska, A., Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp. Toxicol. Pathol., 58, 223–236 (2007).PubMedCrossRefGoogle Scholar
  25. Colalto, C., Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. Pharmacol. Res., 62, 207–227 (2010).PubMedCrossRefGoogle Scholar
  26. Corzo-Martínez, M., Corzo, N., and Villamiel, M., Biological properties of onions and garlic. Trends Food Sci. Tech., 18, 609–625 (2007).CrossRefGoogle Scholar
  27. Crespy, V., Nancoz, N., Oliveira, M., Hau, J., Courtet-Compondu, M. C., and Williamson, G., Glucuronidation of the green tea catechins, (-)-epigallocatechin-3-gallate and (-)-epicatechin-3-gallate, by rat hepatic and intestinal microsomes. Free Radic. Res., 38, 1025–1031 (2004).PubMedCrossRefGoogle Scholar
  28. Cuendet, M., Guo, J., Luo, Y., Chen, S., Oteham, C. P., Moon, R. C., van Breemen, R. B., Marler, L. E., and Pezzuto, J. M., Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice. Cancer Prev. Res. (Phila), 3, 221–232 (2010).CrossRefGoogle Scholar
  29. Dausch, J. G. and Nixon, D. W., Garlic: a review of its relationship to malignant disease. Prev. Med., 19, 346–361 (1990).PubMedCrossRefGoogle Scholar
  30. de Maat, M. M., Hoetelmans, R. M., Math, t R. A., van Gorp, E. C., Meenhorst, P. L., Mulder, J. W., and Beijnen, J. H., Drug interaction between St John’s wort and nevirapine. AIDS, 15, 420–421 (2001).PubMedCrossRefGoogle Scholar
  31. Dhiman, R. K. and Chawla, Y. K., Herbal medicines for liver diseases. Dig. Dis. Sci., 50, 1807–1812 (2005).PubMedCrossRefGoogle Scholar
  32. DiCenzo, R., Shelton, M., Jordan, K., Koval, C., Forrest, A., Reichman, R., and Morse, G., Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy, 23, 866–870 (2003).PubMedCrossRefGoogle Scholar
  33. Ding, T., Tian, S., Zhang, Z., Gu, D., Chen, Y., Shi, Y., and Sun, Z., Determination of active component in silymarin by RP-LC and LC/MS. J. Pharm. Biomed. Anal., 26, 155–161 (2001).PubMedCrossRefGoogle Scholar
  34. Donovan, J. L., DeVane, C. L., Chavin, K. D., Taylor, R. M., and Markowitz, J. S., Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab. Dispos., 31, 519–522 (2003).PubMedCrossRefGoogle Scholar
  35. Dresser, G. K., Schwarz, U. I., Wilkinson, G. R., and Kim, R. B., Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin. Pharmacol. Ther., 73, 41–50 (2003).PubMedCrossRefGoogle Scholar
  36. Dupuis, M. L., Flego, M., Molinari, A., and Cianfriglia, M., Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 Tlymphoblastoid CEMrev cells. HIV Med., 4, 338–345 (2003).PubMedCrossRefGoogle Scholar
  37. Dürr, D., Stieger, B., Kullak-Ublick, G. A., Rentsch, K. M., Steinert, H. C., Meier, P. J., and Fattinger, K., St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther., 68, 598–604 (2000).PubMedCrossRefGoogle Scholar
  38. Eich-Höchli, D., Oppliger, R., Golay, K. P., Baumann, P., and Eap, C. B., Methadone maintenance treatment and St. John’s Wort — a case report. Pharmacopsychiatry, 36, 35–37 (2003).PubMedCrossRefGoogle Scholar
  39. Fischer, V., Vogels, B., Maurer, G., and Tynes, R. E., The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J. Pharmacol. Exp. Ther., 260, 1355–1360 (1992).PubMedGoogle Scholar
  40. Fleming, T., PDR for herbal medicines. Thomson Reuters, New York, (2000).Google Scholar
  41. Fontana, R. J., deVries, T. M., Woolf, T. F., Knapp, M. J., Brown, A. S., Kaminsky, L. S., Tang, B. K., Foster, N. L., Brown, R. R., and Watkins, P. B., Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer’s disease. Br. J. Clin. Pharmacol., 46, 221–228 (1998).PubMedCrossRefGoogle Scholar
  42. Foster, B. C., Foster, M. S., Vandenhoek, S., Krantis, A., Budzinski, J. W., Arnason, J. T., Gallicano, K. D., and Choudri, S., An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J. Pharm. Pharm. Sci., 4, 176–184 (2001).PubMedGoogle Scholar
  43. Fuchikami, H., Satoh, H., Tsujimoto, M., Ohdo, S., Ohtani, H., and Sawada, Y., Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos., 34, 577–582 (2006).PubMedCrossRefGoogle Scholar
  44. Gammans, R. E., Mayol, R. F., and LaBudde, J. A., Metabolism and disposition of buspirone. Am. J. Med., 80, 41–51 (1986).PubMedCrossRefGoogle Scholar
  45. Gaster, B. and Holroyd, J., St John’s wort for depression: a systematic review. Arch. Intern. Med., 160, 152–156 (2000).PubMedCrossRefGoogle Scholar
  46. Gatti, G. and Perucca, E., Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int. J. Clin. Pharmacol. Ther., 32, 614–617 (1994).PubMedGoogle Scholar
  47. Gaudineau, C., Beckerman, R., Welbourn, S., and Auclair, K., Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem. Biophys. Res. Commun., 318, 1072–1078 (2004).PubMedCrossRefGoogle Scholar
  48. Geick, A., Eichelbaum, M., and Burk, O., Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem., 276, 14581–14587 (2001).PubMedCrossRefGoogle Scholar
  49. Gorski, J. C., Jones, D. R., Hamman, M. A., Wrighton, S. A., and Hall, S. D., Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica, 29, 931–944 (1999).PubMedCrossRefGoogle Scholar
  50. Gorski, J. C., Huang, S. M., Pinto, A., Hamman, M. A., Hilligoss, J. K., Zaheer, N. A., Desai, M., Miller, M., and Hall, S. D., The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin. Pharmacol. Ther., 75, 89–100 (2004).PubMedCrossRefGoogle Scholar
  51. Greenblatt, D. J. and Wright, C. E., Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin. Pharmacokinet., 24, 453–471 (1993).PubMedCrossRefGoogle Scholar
  52. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., and Ang, C. Y., Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther., 72, 276–287 (2002).PubMedCrossRefGoogle Scholar
  53. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Carrier, J., Khan, I. A., Edwards, D. J., and Shah, A., In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin. Pharmacol. Ther., 76, 428–440 (2004).PubMedCrossRefGoogle Scholar
  54. Gurley, B. J., Swain, A., Hubbard, M. A., Hartsfield, F., Thaden, J., Williams, D. K., Gentry, W. B., and Tong, Y., Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin. Pharmacol. Ther., 83, 61–69 (2008).PubMedCrossRefGoogle Scholar
  55. Gwilt, P. R., Lear, C. L., Tempero, M. A., Birt, D. D., Grandjean, A. C., Ruddon, R. W., and Nagel, D. L., The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol. Biomarkers Prev., 3, 155–160 (1994).PubMedGoogle Scholar
  56. Harris, J. C., Cottrell, S. L., Plummer, S., and Lloyd, D., Antimicrobial properties of Allium sativum (garlic). Appl. Microbiol. Biotechnol., 57, 282–286 (2001).PubMedCrossRefGoogle Scholar
  57. He, K., Iyer, K. R., Hayes, R. N., Sinz, M. W., Woolf, T. F., and Hollenberg, P. F., Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol., 11, 252–259 (1998).PubMedCrossRefGoogle Scholar
  58. Heimark, L. D., Gibaldi. M., Trager, W. F., O’Reilly, R. A., and Goulart, D. A., The mechanism of the warfarin-rifampin drug interaction in humans. Clin. Pharmacol. Ther., 42, 388–394 (1987).PubMedCrossRefGoogle Scholar
  59. Hellum, B. H. and Nilsen, O. G., In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin. Pharmacol. Toxicol., 102, 466–475 (2008).PubMedCrossRefGoogle Scholar
  60. Henderson, G. L., Harkey, M. R., Gershwin, M. E., Hackman, R. M., Stern, J. S., and Stresser, D. M., Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci., 65, PL209–PL214 (1999).PubMedCrossRefGoogle Scholar
  61. Jancová, P., Anzenbacherová, E., Papousková, B., Lemr, K., Luzná, P., Veinlichová, A., Anzenbacher, P., and Simánek, V., Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab. Dispos., 35, 2035–2039 (2007).PubMedCrossRefGoogle Scholar
  62. Jia, C., Shi, H., Jin, W., Zhang, K., Jiang, Y., Zhao, M., and Tu, P., Metabolism of echinacoside, a good antioxidant, in rats: isolation and identification of its biliary metabolites. Drug Metab. Dispos., 37, 431–438 (2009).PubMedCrossRefGoogle Scholar
  63. Jiang, X., Williams, K. M., Liauw, W. S., Ammit, A. J., Roufogalis, B. D., Duke, C. C., Day, R. O., and McLachlan, A. J., Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol., 57, 592–599 (2004).PubMedCrossRefGoogle Scholar
  64. Jodoin, J., Demeule, M., and Beliveau, R., Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta, 1542, 149–159 (2002).PubMedCrossRefGoogle Scholar
  65. Johne, A., Schmider, J., Brockmöller, J., Stadelmann, A. M., Störmer, E., Bauer, S., Scholler, G., Langheinrich, M., and Roots, I., Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J. Clin. Psychopharmacol., 22, 46–54 (2002).PubMedCrossRefGoogle Scholar
  66. Juan, M. E., González-Pons, E., and Planas, J. M., Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J. Nutr., 140, 489–495 (2010).PubMedCrossRefGoogle Scholar
  67. Kasper, S., Gastpar, M., Müller, W. E., Volz, H. P., Dienel, A., Kieser, M., and Möller, H. J., Efficacy of St. John’s wort extract WS® 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. Eur. Arch. Psychiatry Clin. Neurosci., 258, 59–63 (2008).PubMedCrossRefGoogle Scholar
  68. Kent, U. M., Aviram, M., Rosenblat, M., and Hollenberg, P. F., The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab. Dispos., 30, 709–715 (2002).PubMedCrossRefGoogle Scholar
  69. Kim, A. E., Dintaman, J. M., Waddell, D. S., and Silverman, J. A., Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther., 286, 1439–1445 (1998).PubMedGoogle Scholar
  70. Kim, D. H., Jin, Y. H., Park, J. B., and Kobashi, K., Silymarin and its components are inhibitors of beta-glucuronidase. Biol. Pharm. Bull., 17, 443–445 (1994).PubMedCrossRefGoogle Scholar
  71. Kim, H. J., Chun, Y. J., Park, J. D., Kim, S. I., Roh, J. K., and Jeong, T. C., Protection of rat liver microsomes against carbon tetrachloride-induced lipid peroxidation by red ginseng saponin through cytochrome P450 inhibition. Planta Med., 63, 415–418 (1997).PubMedCrossRefGoogle Scholar
  72. Kinghorn, A. D. and Compadre, C. M., Less common high potency sweeteners. In AlternatiVe Sweeteners, Third Editions Revised and Expanded; O’Brien Nabors, L. (Ed.). Marcel Dekker, New York, pp. 209–231, (2001).Google Scholar
  73. Kren, V., Ulrichová, J., Kosina, P., Stevenson, D., Sedmera, P., Prikrylová, V., Halada, P., and Simánek, V., Chemoenzymatic preparation of silybin beta-glucuronides and their biological evaluation. Drug Metab. Dispos., 28, 1513–1517 (2000).PubMedGoogle Scholar
  74. Kvasnicka, F., Bíba, B., Sevcík, R., Voldrich, M., and Krátká, J., Analysis of the active components of silymarin. J. Chromatogr. A, 990, 239–245 (2003).PubMedCrossRefGoogle Scholar
  75. Kyo, E., Uda, N., Kasuga, S., and Itakura, Y., Immunomodulatory effects of aged garlic extract. J. Nutr., 131, 1075S–1079S (2001).PubMedGoogle Scholar
  76. Leber, H. W. and Knauff, S., Influence of silymarin on drug metabolizing enzymes in rat and man. Arzneimittelforschung, 26, 1603–1605 (1976).PubMedGoogle Scholar
  77. Lebot, V. and Lévesque, J., The origin and distribution of kava (Piper methysticum Forst. f. and Piper wichmannii C. DC., Piperace-ae): a phytochemical approach. Allertonia, 5, 223–280 (1989).Google Scholar
  78. Lee, L. S., Andrade, A. S., and Flexner, C., Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin. Infect. Dis., 43, 1052–1059 (2006).PubMedCrossRefGoogle Scholar
  79. Lim, S. T., Dragull, K., Tang, C. S., Bittenbender, H. C., Efird, J. T., and Nerurkar, P. V., Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol. Sci., 97, 214–221 (2007).PubMedCrossRefGoogle Scholar
  80. Lin, M. C., Wang, E. J., Patten, C., Lee, M. J., Xiao, F., Reuhl, K. R., and Yang, C. S., Protective effect of diallyl sulfone against acetaminophen-induced hepatotoxicity in mice. J. Biochem. Toxicol., 11, 11–20 (1996).PubMedCrossRefGoogle Scholar
  81. Lorenz, D., Mennicke, W, H., and Behrendt, W., Untersuchungen zur Elimination von Silymarin bei cholezystektomierten Patienten. Planta Med., 45, 216–223 (1982).CrossRefGoogle Scholar
  82. Lu, H., Meng, X., Li, C., Sang, S., Patten, C., Sheng, S., Hong, J., Bai, N., Winnik, B., Ho, C. T., and Yang, C. S., Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab. Dispos., 31, 452–461 (2003).PubMedCrossRefGoogle Scholar
  83. Lü, J. M., Yao, Q., and Chen, C., Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr. Vasc. Pharmacol., 7, 293–302 (2009).PubMedCrossRefGoogle Scholar
  84. Mackenzie, P. I., Gregory, P. A., Gardner-Stephen, D. A., Lewinsky, R. H., Jorgensen, B. R., Nishiyama, T., Xie, W., and Radominska-Pandya, A., Regulation of UDP glucuronosyltransferase genes. Curr. Drug Metab., 4, 249–257 (2003).PubMedCrossRefGoogle Scholar
  85. Mai, I., Störmer, E., Bauer, S., Krüger, H., Budde, K., and Roots, I., Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol. Dial. Transplant., 18, 819–822 (2003).PubMedCrossRefGoogle Scholar
  86. Manyike, P. T., Kharasch, E. D., Kalhorn, T. F., and Slattery, J. T., Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin. Pharmacol. Ther., 67, 275–282 (2000).PubMedCrossRefGoogle Scholar
  87. Markowitz, J. S., DeVane, C. L., Boulton, D. W., Carson, S. W., Nahas, Z., and Risch, S. C., Effect of St. John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci., 66, PL133–PL139 (2000).PubMedCrossRefGoogle Scholar
  88. Markowitz, J. S., Donovan, J. L., Lindsay DeVane, C., Sipkes, L., and Chavin, K. D., Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J. Clin. Psychopharmacol., 23, 576–581 (2003a).PubMedCrossRefGoogle Scholar
  89. Markowitz, J. S., Donovan, J. L., Devane, C. L., Taylor, R. M., Ruan, Y., Wang, J. S., and Chavin, K. D., Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin. Pharmacol. Ther., 74, 536–542 (2003b).PubMedCrossRefGoogle Scholar
  90. Markowitz, J. S., Devane, C. L., Chavin, K. D., Taylor, R. M., Ruan, Y., and Donovan, J. L., Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin. Pharmacol. Ther., 74, 170–177 (2003c).PubMedCrossRefGoogle Scholar
  91. Mathews, J. M., Etheridge, A. S., Valentine, J. L., Black, S. R., Coleman, D. P., Patel, P., So, J., and Burka, L. T., Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab. Dispos., 33, 1555–1563 (2005).PubMedCrossRefGoogle Scholar
  92. Mathijssen, R. H., Verweij, J., de Bruijn, P., Loos, W. J., and Sparreboom, A., Effects of St. John’s wort on irinotecan metabolism. J. Natl. Cancer Inst., 94, 1247–1249 (2002).PubMedCrossRefGoogle Scholar
  93. Matthias, A., Gillam, E. M., Penman, K. G., Matovic, N. J., Bone, K. M., De Voss, J. J., and Lehmann, R. P., Cytochrome P450 enzyme-mediated degradation of Echinacea alkylamides in human liver microsomes. Chem. Biol. Interact., 155, 62–70 (2005).PubMedCrossRefGoogle Scholar
  94. McRae, S., Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ, 155, 293–295 (1996).PubMedGoogle Scholar
  95. Mohamed, M. E. and Frye, R. F., Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med., 77, 311–321 (2011a).PubMedCrossRefGoogle Scholar
  96. Mohamed, M. E. and Frye, R. F., Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. Drug Metab. Dispos., 39, 1522–1528 (2011b).PubMedCrossRefGoogle Scholar
  97. Mohamed, M. F. and Frye, R. F., Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. Drug Metab. Dispos., 38, 270–275 (2010).PubMedCrossRefGoogle Scholar
  98. Mohamed, M. F., Tseng, T., and Frye, R. F., Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. Xenobiotica, 40, 663–669 (2010).PubMedCrossRefGoogle Scholar
  99. Moon, A. and Kim, S. H., Effect of Glycyrrhiza glabra roots and glycyrrhizin on the glucuronidation in rats. Planta Med., 63, 115–119 (1997).PubMedCrossRefGoogle Scholar
  100. Nabekura, T., Yamaki, T., Ueno, K., and Kitagawa, S., Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother. Pharmacol., 62, 867–873 (2008).PubMedCrossRefGoogle Scholar
  101. Najar, I. A., Sachin, B. S., Sharma, S. C., Satti, N. K., Suri, K. A., and Johri, R. K., Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother. Res., 24, 454–458 (2010).PubMedCrossRefGoogle Scholar
  102. Nebel, A., Schneider, B. J., Baker, R. K., and Kroll, D. J., Potential metabolic interaction between St. John’s wort and theophylline. Ann. Pharmacother., 33, 502 (1999).PubMedCrossRefGoogle Scholar
  103. Netsch, M. I., Gutmann, H., Luescher, S., Brill, S., Schmidlin, C. B., Kreuter, M. H., and Drewe, J., Inhibitory activity of a green tea extract and some of its constituents on multidrug resistance-associated protein 2 functionality. Planta Med., 71, 135–141 (2005).PubMedCrossRefGoogle Scholar
  104. Netsch, M. I., Gutmann, H., Schmidlin, C. B., Aydogan, C., and Drewe, J., Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med., 72, 514–520 (2006).PubMedCrossRefGoogle Scholar
  105. Nguyen, H., Zhang, S., and Morris, M. E., Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci., 92, 250–257 (2003).PubMedCrossRefGoogle Scholar
  106. Nguyen, T. D., Villard, P. H., Barlatier, A., Elsisi, A. E., Jouve, E., Duc, N. M., Sauze, C., Durand, A., and Lacarelle, B., Panax vietnamensis protects mice against carbon tetrachloride-induced hepatotoxicity without any modification of CYP2E1 gene expression. Planta Med., 66, 714–719 (2000).PubMedCrossRefGoogle Scholar
  107. Nishikawa, M., Ariyoshi, N., Kotani, A., Ishii, I., Nakamura, H., Nakasa, H., Ida, M., Nakamura, H., Kimura, N., Kimura, M., Hasegawa, A., Kusu, F., Ohmori, S., Nakazawa, K., and Kitada, M., Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam. Drug Metab. Pharmacokinet., 19, 280–289 (2004).PubMedCrossRefGoogle Scholar
  108. Obach, R. S., Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther., 294, 88–95 (2000).PubMedGoogle Scholar
  109. Okerholm, R. A., Weiner, D. L., Hook, R. H., Walker, B. J., Leeson, G. A., Biedenbach, S. A., Cawein, M. J., Dusebout, T. D., Wright, G. J., Myers, M., Schindler, V., and Cook, C. E., Bioavailability of terfenadine in man. Biopharm. Drug Dispos., 2, 185–190 (1981).PubMedCrossRefGoogle Scholar
  110. Oliveira, E. J. and Watson, D. G., In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes. FEBS Lett., 471, 1–6 (2000).PubMedCrossRefGoogle Scholar
  111. Paolini, M., Pozzetti, L., Sapone, A., and Cantelli-Forti, G., Effect of licorice and glycyrrhizin on murine liver CYPdependent monooxygenases. Life Sci., 62, 571–582 (1998).PubMedCrossRefGoogle Scholar
  112. Pirmohamed, M., Williams, D., Madden, S., Templeton, E., and Park, B. K., Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther., 272, 984–990 (1995).PubMedGoogle Scholar
  113. Piscitelli, S. C., Burstein, A. H., Chaitt, D., Alfaro, R. M., and Falloon, J., Indinavir concentrations and St John’s wort. Lancet, 355, 547–548 (2000).PubMedCrossRefGoogle Scholar
  114. Piscitelli, S. C., Formentini, E., Burstein, A. H., Alfaro, R., Jagannatha, S., and Falloon, J., Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy, 22, 551–556 (2002).PubMedCrossRefGoogle Scholar
  115. Piver, B., Berthou, F., Dreano, Y., and Lucas, D., Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol. Lett., 125, 83–91 (2001).PubMedCrossRefGoogle Scholar
  116. Piver, B., Berthou, F., Dreano, Y., and Lucas, D., Differential inhibition of human cytochrome P450 enzymes by epsilonviniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci., 73, 1199–1213 (2003).PubMedCrossRefGoogle Scholar
  117. Quaglia, M. G., Bossù, E., Donati, E., Mazzanti, G., and Brandt, A., Determination of silymarine in the extract from the dried silybum marianum fruits by high performance liquid chromatography and capillary electrophoresis. J. Pharm. Biomed. Anal., 19, 435–442 (1999).PubMedCrossRefGoogle Scholar
  118. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., and Trager, W. F., Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol., 5, 54–59 (1992).PubMedCrossRefGoogle Scholar
  119. Roby, C. A., Anderson, G. D., Kantor, E., Dryer, D. A., and Burstein, A. H., St John’s Wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther., 67, 451–457 (2000).PubMedCrossRefGoogle Scholar
  120. Ross, S. M., Milk thistle (Silybum marianum): an ancient botanical medicine for modern times. Holist. Nurs. Pract., 22, 299–300 (2008).PubMedGoogle Scholar
  121. Schandalik, R., Gatti, G., and Perucca, E., Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung, 42, 964–968 (1992).PubMedGoogle Scholar
  122. Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., and Borst, P., Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest., 96, 1698–1705 (1995).PubMedCrossRefGoogle Scholar
  123. Schulz, H. U., Schürer, M., Krumbiegel, G., Wächter, W., Weyhenmeyer, R., and Seidel, G., The solubility and bioequivalence of silymarin preparations. Arzneimittelforschung, 45, 61–64 (1995).PubMedGoogle Scholar
  124. Sinescu, I., Geavlete, P., Multescu, R., Gangu, C., Miclea, F., Coman, I., Ioiart, I., Ambert, V., Constantin, T., Petrut, B., and Feciche, B., Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urol. Int., 86, 284–289 (2011).PubMedCrossRefGoogle Scholar
  125. Singh, U. P., Prithiviraj, B., Sarma, B. K., Singh, M., and Ray, A. B., Role of garlic (Allium sativum L.) in human and plant diseases. Indian J. Exp. Biol., 39, 310–322 (2001).PubMedGoogle Scholar
  126. Singh, Y. N. and Singh, N. N., Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs, 16, 731–743 (2002).PubMedCrossRefGoogle Scholar
  127. Sonoda, J., Xie, W., Rosenfeld, J. M., Barwick, J. L., Guzelian, P. S., and Evans, R. M., Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc. Natl. Acad. Sci. U. S. A., 99, 13801–13806 (2002).PubMedCrossRefGoogle Scholar
  128. Spaldin, V., Madden, S., Adams, D. A., Edwards, R. J., Davies, D. S., and Park, B. K., Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab. Dispos., 23, 929–934 (1995).PubMedGoogle Scholar
  129. Sparreboom, A., Cox, M. C., Acharya, M. R., and Figg, W. D., Herbal remedies in the United States: potential adverse interactions with anticancer agents. J. Clin. Oncol., 22, 2489–2503 (2004).PubMedCrossRefGoogle Scholar
  130. Sridar, C., Goosen, T. C., Kent, U. M., Williams, J. A., and Hollenberg, P. F., Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos., 32, 587–594 (2004).PubMedCrossRefGoogle Scholar
  131. Standish, L. J., Greene, K. B., Bain, S., Reeves, C., Sanders, F., Wines, R. C., Turet, P., Kim, J. G., and Calabrese, C., Alternative medicine use in HIV-positive men and women: demographics, utilization patterns and health status. AIDS Care, 13, 197–208 (2001).PubMedCrossRefGoogle Scholar
  132. Sugimoto, K., Ohmori, M., Tsuruoka, S., Nishiki, K., Kawaguchi, A., Harada, K., Arakawa, M., Sakamoto, K., Masada, M., Miyamori, I., and Fujimura, A., Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin. Pharmacol. Ther., 70, 518–524 (2001).PubMedCrossRefGoogle Scholar
  133. Sun, X. Y., Plouzek, C. A., Henry, J. P., Wang, T. T., and Phang, J. M., Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. Cancer Res., 58, 2379–2384 (1998).PubMedGoogle Scholar
  134. Tang, J., Sun, J., Zhang, Y., Li, L., Cui, F., and He, Z., Herbdrug interactions: Effect of Ginkgo biloba extract on the pharmacokinetics of theophylline in rats. Food Chem. Toxicol., 45, 2441–2445 (2007).PubMedCrossRefGoogle Scholar
  135. Tierra, M., Echinacea: an effective alternative to antibiotics. J. Herb. Pharmacother., 7, 79–89 (2007).PubMedGoogle Scholar
  136. Toselli, F., Matthias, A., and Gillam, E. M., Echinacea metabolism and drug interactions: the case for standardization of a complementary medicine. Life Sci., 85, 97–106 (2009).PubMedCrossRefGoogle Scholar
  137. Tu, J. H., He, Y. J., Chen, Y., Fan, L., Zhang, W., Tan, Z. R., Huang, Y. F., Guo, D., Hu, D. L., Wang, D., and Hong-Hao, Z., Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur. J. Clin. Pharmacol., 66, 805–810 (2010).PubMedCrossRefGoogle Scholar
  138. Unger, M., Holzgrabe, U., Jacobsen, W., Cummins, C., and Benet, L. Z., Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med., 68, 1055–1058 (2002).PubMedCrossRefGoogle Scholar
  139. van de Wetering, K., Burkon, A., Feddema, W., Bot, A., de Jonge, H., Somoza, V., and Borst, P., Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol. Pharmacol., 75, 876–885 (2009).PubMedCrossRefGoogle Scholar
  140. van der Logt, E. M., Roelofs, H. M., Nagengast, F. M., and Peters, W. H., Induction of rat hepatic and intestinal UDPglucuronosyltransferases by naturally occurring dietary anticarcinogens. Carcinogenesis, 24, 1651–1656 (2003).PubMedCrossRefGoogle Scholar
  141. van Erp, N. P., Baker, S. D., Zhao, M., Rudek, M. A., Guchelaar, H. J., Nortier, J. W., Sparreboom, A., and Gelderblom, H., Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin. Cancer Res., 11, 7800–7806 (2005).PubMedCrossRefGoogle Scholar
  142. Venkatakrishnan, K., von Moltke, L. L., and Greenblatt, D. J., Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J. Clin. Pharmacol., 39, 567–577 (1999).PubMedCrossRefGoogle Scholar
  143. Venkataramanan, R., Ramachandran, V., Komoroski, B. J., Zhang, S., Schiff, P. L., and Strom, S. C., Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab. Dispos., 28, 1270–1273 (2000).PubMedGoogle Scholar
  144. Volak, L. P. and Court, M. H., Role for protein kinase C delta in the functional activity of human UGT1A6: implications for drug-drug interactions between PKC inhibitors and UGT1A6. Xenobiotica, 40, 306–318 (2010).PubMedCrossRefGoogle Scholar
  145. Volz, H. P. and Kieser, M., Kava-kava extract WS® 1490 versus placebo in anxiety disorders-a randomized placebocontrolled 25-week outpatient trial. Pharmacopsychiatry, 30, 1–5 (1997).PubMedCrossRefGoogle Scholar
  146. von Moltke, L. L., Weemhoff, J. L., Bedir, E., Khan, I. A., Harmatz, J. S., Goldman, P., and Greenblatt, D. J., Inhibition of human cytochromes P450 by components of Ginkgo biloba. J. Pharm. Pharmacol., 56, 1039–1044 (2004).CrossRefGoogle Scholar
  147. Wang, R. W., Liu, L., and Cheng, H., Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab. Dispos., 24, 786–791 (1996).PubMedGoogle Scholar
  148. Wang, Z., Gorski, J. C., Hamman, M. A., Huang, S. M., Lesko, L. J., and Hall, S. D., The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther., 70, 317–326 (2001).PubMedGoogle Scholar
  149. Weyhenmeyer, R., Mascher, H., and Birkmayer, J., Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int. J. Clin. Pharmacol. Ther. Toxicol., 30, 134–138 (1992).PubMedGoogle Scholar
  150. Williams, D. and Feely, J., Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet., 41, 343–370 (2002a).PubMedCrossRefGoogle Scholar
  151. Williams, J. A., Ring, B. J., Cantrell, V. E., Campanale, K., Jones, D. R., Hall, S. D., and Wrighton, S. A., Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab. Dispos., 30, 1266–1273 (2002b).PubMedCrossRefGoogle Scholar
  152. Woelkart, K., Linde, K., and Bauer, R., Echinacea for preventing and treating the common cold. Planta Med., 74, 633–637 (2008).PubMedCrossRefGoogle Scholar
  153. Wu, D. and Cederbaum, A. I., Oxidative stress mediated toxicity exerted by ethanol-inducible CYP2E1. Toxicol. Appl. Pharmacol., 207, 70–76 (2005).PubMedCrossRefGoogle Scholar
  154. Xiang, Y. Z., Shang, H. C., Gao, X. M., and Zhang, B. L., A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother. Res., 22, 851–858 (2008).PubMedCrossRefGoogle Scholar
  155. Yang, L., Deng, Y., Xu, S., and Zeng, X., In vivo pharmacokinetic and metabolism studies of ginsenoside Rd. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 854, 77–84 (2007).PubMedCrossRefGoogle Scholar
  156. Yu, X. Y., Lin, S. G., Zhou, Z. W., Chen, X., Liang, J., Yu, X. Q., Chowbay, B., Wen, J. Y., Duan, W., Chan, E., Li, X. T., Cao, J., Li, C. G., Xue, C. C., and Zhou, S. F., Role of Pglycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of Glycyrrhiza glabra. Pharm. Res., 24, 1668–1690 (2007).PubMedCrossRefGoogle Scholar
  157. Zhang, S. and Morris, M. E., Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther., 304, 1258–1267 (2003).PubMedCrossRefGoogle Scholar
  158. Zou, L., Harkey, M. R., and Henderson, G. L., Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci., 71, 1579–1589 (2002).PubMedCrossRefGoogle Scholar
  159. Zuber, R., Modrianský, M., Dvorák, Z., Rohovský, P., Ulrichová, J., Simánek, V., and Anzenbacher, P., Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother. Res., 16, 632–638 (2002).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2011

Authors and Affiliations

  • Young Hee Choi
    • 1
  • Young-Won Chin
    • 1
  • Yoon Gyoon Kim
    • 2
  1. 1.College of PharmacyDongguk University-SeoulSeoulKorea
  2. 2.College of PharmacyDankook UniversityChonanKorea

Personalised recommendations